Why Tesla Was One of the Worst-Performing Stocks in the S&P 500 in the First Quarter
Tesla was one of the worst-performing stocks in the S&P 500 in the first quarter, with shares losing more than a third of their value since the start of 2025.
Tesla was one of the worst-performing stocks in the S&P 500 in the first quarter, with shares losing more than a third of their value since the start of 2025.
Markets around the world continue to sink on fears about President Donald Trump's protectionist trade policies, and investors keep plowing money into gold, with futures hitting another record high Monday. Trump's latest round of tariffs roll out Wednesday, which Trump has been calling “Liberation Day.” Interest in buying gold can rise sharply in times of uncertainty, as anxious investors seek safe havens for their money.
The S&P 500 and Nasdaq logged their worst performance since Russia’s invasion of Ukraine slammed into the global economy.
The Magnificent Seven declined on Monday, capping off the worst month and quarter on record for the group of big tech stocks that account for more than a quarter of the S&P 500's market value.
One quarter into 2025, CVS Health has risen the most of any stock in the S&P 500, with a share price that has popped 50% since the start of the year.
The S&P 500 gained 0.6% on Monday, March 31, boosted by an afternoon rally even as investors brace for the planned onset of reciprocal tariffs later this week.
NEW YORK (Reuters) -As Wall Street draws the curtain on a tumultuous quarter in which stocks logged a record high before tumbling into correction, investors are faced with a mountain of policy uncertainty that clouds the outlook for coming quarters. The S&P 500 Index finished the quarter down 4.6%, its worst first three months of a year since the first quarter of 2022. Investors, who started the year with high hopes for pro-growth policies from the Trump administration, have been spooked by a barrage of tariff-related headlines.
Fashion conglomerate PVH (NYSE:PVH) beat Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 4.8% year on year to $2.37 billion. Its non-GAAP profit of $3.27 per share was 1.8% above analysts’ consensus estimates.
Shares of energy drink company Celsius (NASDAQ:CELH) jumped 8.9% in the afternoon session after Truist analysts upgraded the stock's rating from Hold to Buy and raised the price target from $35 to $45. The analysts added, "In our opinion, the market is already looking past the hiccups of the legacy business in 2024 and the brand's slowdown in 1Q25."
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 12.5% in the morning session after Peter Marks, the head of the FDA's Center for Biologics Evaluation and Research (CBER), resigned on Friday, 28 March 2025. Marks noted his departure was related to "misinformation and lies" around immunization and raised concerns about the Trump administration's ability to "swiftly approve critical vaccines."